image description

Tag: Resolve Therapeutics

Study Shows Need for Greater Awareness of Biologics for Lupus

August 19, 2019 A new study led by Dr. S. Sam Lim of Emory University found a need for more awareness of biologic therapies among both black and white people with lupus.  Biologics are medicines that come from living cells to prevent, treat and cure human diseases, and are designed to have specific effects on […] Read More

New Trial of Promising Lupus Treatment RSLV-132 Has Finished Enrolling Patients

July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132.  Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […] Read More

LRA Grant Leads to New Drug Candidate RSLV-132

May 10, 2019 Grant support from the Lupus Research Alliance (then ALR) supported early work that led to a potential new drug, RSLV-132. In lupus, antibodies can target DNA’s chemical cousin RNA, which performs a variety of jobs in cells. When these antibodies encounter an RNA molecule, they attach to it, forming clusters that can […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates